Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 5:41 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 785 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Gene Expression Clear all
Terminated Phase 1 Interventional

A Gene Transfer Therapy to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Therapeutic Plasma Exchange (Plasmapheresis) in Participants With Duchenne Muscular Dystrophy (DMD) and Pre-existing Antibodies to AAVrh74

NCT06597656
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
delandistrogene moxeparvovec, Plasmapheresis
Genetic · Procedure
Lead sponsor
Sarepta Therapeutics, Inc.
Industry
Eligibility
4 Years to 8 Years · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Gainesville, Florida • St Louis, Missouri • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Nov 13, 2026, 5:41 AM EST
Completed Phase 2 Interventional Results available

A Multi-Histology Phase II Study of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine (FdCyd + THU)

NCT00978250
View directory record Official record
Conditions
Head and Neck Neoplasms, Lung Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms
Interventions
5-Fluoro-2'-Deoxycytidine (FdCyd) + Tetrahydrouridine (THU)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
4
States / cities
Davis, California • Duarte, California • South Pasadena, California + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2019 · Synced Nov 13, 2026, 5:41 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

White Adipose Tissue Clocks and High Calorie Feeding

NCT02809482
View directory record Official record
Conditions
Healthy
Interventions
Eucaloric feeding, Overfeeding
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
20 Years to 35 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 1, 2019 · Synced Nov 13, 2026, 5:41 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Allele-specific Expression of a Bitter Taste Receptor

NCT02766959
View directory record Official record
Conditions
Rhinosinusitis
Interventions
Observational study
Other
Lead sponsor
Monell Chemical Senses Center
Other
Eligibility
21 Years to 50 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
3
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 18, 2018 · Synced Nov 13, 2026, 5:41 AM EST
Terminated Phase 1 Interventional Accepts healthy volunteers

[18F]DASA-23 and PET Scan in Evaluating Pyruvate Kinase M2 Expression in Patients With Intracranial Tumors or Recurrent Glioblastoma and Healthy Volunteers

NCT03539731
View directory record Official record
Conditions
Healthy Subject, Intracranial Neoplasm, Glioblastoma
Interventions
Fluorine F 18 DASA-23, Positron Emission Tomography
Drug · Procedure
Lead sponsor
Guido A. Davidzon, MD, SM
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2024 · Synced Nov 13, 2026, 5:41 AM EST
Active, not recruiting No phase listed Observational

Blood Biomarkers in Pediatric Kidney Transplant Recipients

NCT05477082
View directory record Official record
Conditions
Rejection of Kidney Allograft
Interventions
Observational group
Other
Lead sponsor
University of Minnesota
Other
Eligibility
Up to 21 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 13, 2026, 5:41 AM EST
Completed Phase 2 Interventional Results available

Futibatinib and Pembrolizumab for Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver Cancer

NCT04828486
View directory record Official record
Conditions
Advanced Hepatocellular Carcinoma, BCLC Stage A Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
Interventions
Futibatinib, Pembrolizumab, Quality-of-Life Assessment
Drug · Biological · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Nov 13, 2026, 5:41 AM EST
Terminated No phase listed Observational

LCI-GU-BLA-SPEC-001: Aurora Kinase Expression in Muscle-Invasive Bladder Cancer

NCT02164942
View directory record Official record
Conditions
Bladder Cancer
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 26, 2022 · Synced Nov 13, 2026, 5:41 AM EST
Terminated Phase 2 Interventional Results available

DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer

NCT03505710
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Trastuzumab deruxtecan
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
9
States / cities
La Jolla, California • Aurora, Colorado • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated May 30, 2025 · Synced Nov 13, 2026, 5:41 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Expression of Longevity Genes in Response to Extended Fasting

NCT01059760
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Fasting First, Fed First
Behavioral
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Jul 17, 2017 · Synced Nov 13, 2026, 5:41 AM EST
Recruiting Phase 1 Interventional

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

NCT07029399
View directory record Official record
Conditions
HR+ Breast Cancer, Triple Negative Breast Cancer (TNBC), CCNE1 Amplified Advanced Solid Tumors, HR+ HER2- Breast Cancer
Interventions
NKT5097 CDK2/CDK4 dual degrader, Fulvestrant, Letrozole
Drug
Lead sponsor
NiKang Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
19
States / cities
Duarte, California • La Jolla, California • Denver, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2026 · Synced Nov 13, 2026, 5:41 AM EST
Terminated No phase listed Observational Results available

Evaluation of Molecular Markers in Adrenal Tumors

NCT01348698
View directory record Official record
Conditions
Adrenal Gland Neoplasms
Interventions
Tumor tissue biopsy, Surgery
Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 90 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 26, 2018 · Synced Nov 13, 2026, 5:41 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Targeted Nutrition for Moderate to Late Preterm Infants

NCT05515614
View directory record Official record
Conditions
Premature Birth, Breastmilk Collection, Postnatal Growth Restriction
Interventions
Targeted Fortification, Enfamil Liquid Human Milk Fortifier
Dietary Supplement
Lead sponsor
Loma Linda University
Other
Eligibility
Not listed
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Nov 13, 2026, 5:41 AM EST
Completed No phase listed Observational Accepts healthy volunteers

The Natural History of Gene Expression in the Lung Cells of Non-Smokers, Smokers and Ex-Smokers in Health and Disease

NCT00974064
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD), Smoking, Smoking Cessation, Chronic Bronchitis, Emphysema
Interventions
Not listed
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Nov 13, 2026, 5:41 AM EST
Completed Not applicable Interventional

Global Profiling of Gene and Protein Expression Associated With Coronary Heart Disease Reversal

NCT01805492
View directory record Official record
Conditions
Heart Diseases, Cardiovascular Diseases
Interventions
Dr. Dean Ornish Program for Reversing Heart Disease
Behavioral
Lead sponsor
Windber Research Institute
Other
Eligibility
21 Years and older
Enrollment
422 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
1
States / cities
Windber, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 6, 2013 · Synced Nov 13, 2026, 5:41 AM EST
Completed Phase 3 Interventional

Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence

NCT01479244
View directory record Official record
Conditions
Breast Cancer With Low to Intermediate HER2 Expression
Interventions
NeuVax™ vaccine, Leukine® (sargramostim, GM-CSF) and water for injection
Biological
Lead sponsor
Galena Biopharma, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
758 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
81
States / cities
Bessemer, Alabama • Mobile, Alabama • Peoria, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Nov 13, 2026, 5:41 AM EST
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Caring Relationships Expression Study

NCT05627687
View directory record Official record
Conditions
Caregiver Burden, Anxiety, Stress
Interventions
Heart Rate Variability Biofeedback, Music Listening Control
Behavioral
Lead sponsor
Arizona State University
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 12, 2024 · Synced Nov 13, 2026, 5:41 AM EST
Withdrawn No phase listed Observational Accepts healthy volunteers

Studies on the Expression and Functions of RLIP76 in Blood Samples of Healthy Human Subjects

NCT00762801
View directory record Official record
Conditions
Healthy
Interventions
Not listed
Lead sponsor
University of North Texas Health Science Center
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
2
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Oct 26, 2016 · Synced Nov 13, 2026, 5:41 AM EST
Terminated Phase 2 Interventional Results available

A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma

NCT03947255
View directory record Official record
Conditions
Hodgkin Lymphoma, Peripheral T Cell Lymphoma, Anaplastic Large Cell Lymphoma
Interventions
brentuximab vedotin
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
19
States / cities
Anaheim, California • Lafayette, Colorado • Pembroke Pines, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2023 · Synced Nov 13, 2026, 5:41 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Improving Lactation Success in Mothers of Critically Infants

NCT04097860
View directory record Official record
Conditions
Breast Pumping
Interventions
Text message including biomarker of breast pumping adequacy
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older · Female only
Enrollment
122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 28, 2025 · Synced Nov 13, 2026, 5:41 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Mechanisms of Immune Tolerance and Inflammation in Patients With Cystic Fibrosis With ABPA

NCT00585364
View directory record Official record
Conditions
Cystic Fibrosis, Allergic Bronchopulmonary Aspergillosis
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
6 Years and older
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 15, 2016 · Synced Nov 13, 2026, 5:41 AM EST
Terminated No phase listed Observational

Effect of Sorafenib or Regorafenib on P63 Expression and Keratinocyte Differentiation in Human Skin

NCT01466504
View directory record Official record
Conditions
Renal Cell Carcinoma, Hepatocellular Carcinoma, Colorectal Carcinoma
Interventions
skin punch biopsy
Procedure
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Lebanon, New Hampshire • White River Junction, Vermont
Source: ClinicalTrials.gov public record
Updated Apr 15, 2013 · Synced Nov 13, 2026, 5:41 AM EST
Completed No phase listed Observational Accepts healthy volunteers

A Longitudinal, Observational Biomarker Study in Participants With Primary Sjogren's Syndrome

NCT02422407
View directory record Official record
Conditions
Healthy, Sicca Syndrome, Sjögren's Syndrome
Interventions
Biopsy
Procedure
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
4
States / cities
Hartford, Connecticut • Boston, Massachusetts • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2018 · Synced Nov 13, 2026, 5:41 AM EST
Withdrawn No phase listed Observational

Clinician Utilization of Corus CAD (or ASGES) in Primary Care Provider Decision Making

NCT02158754
View directory record Official record
Conditions
Coronary Artery Disease, Angina Pectoris, Chest Pain, Cardiovascular Diseases, CAD, CVD, Coronary Heart Disease, CHD
Interventions
Corus CAD (ASGES)
Diagnostic Test
Lead sponsor
CardioDx
Industry
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
9
States / cities
Rutherford, New Jersey • Wake Forest, North Carolina • Youngstown, Ohio + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2019 · Synced Nov 13, 2026, 5:41 AM EST